{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"19","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Descriptive summary of daratumumab administration. Number of doses of daratumumab received.","dispersionType":"Full Range","groups":[{"description":"Induction: Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab\n\nCarfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab: Experimental","id":"OG000","title":"KRd-Daratumumab"}],"paramType":"MEDIAN","populationDescription":"The evaluable population is defined as all subjects who initiate treatment with daratumumab","reportingStatus":"POSTED","timeFrame":"From enrollment to completion of induction; evaluated for approximately 32 weeks (8 28-day cycles).","title":"Daratumumab Administration - Number of Doses Received","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"count of doses"}